Trial site
Kindai University Hospital
Sayama, Osaka 589-8511, JapanNot linked to an institution yet
- 12running trials
- 8closed trials
The trials here
What the 20 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 24 trials
- Phase 11 trial
- Phase 1/21 trial
- Status
- Active, not recruiting8 trials
- Completed7 trials
- Recruiting4 trials
- Terminated1 trial
- Lead sponsor
- Pfizer3 trials
- Incyte Corporation2 trials
- Kyowa Kirin Co., Ltd.2 trials
- Takeda2 trials
- ARCAGY/ GINECO GROUP1 trial
- and 10 more
Running trials
Recruiting
TheraSphere Japan Pre-Market Study
NCT07377487· Boston Scientific Corporation· Source
Contact: Clinical Trial Office
Active, not recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
NCT06558279· Phase 3· argenx· Source
Recruiting
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
NCT06476184· Phase 3· ARCAGY/ GINECO GROUP· Source
Contact: Hidekatsu NAKAI
Active, not recruiting
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916· Phase 2· Kyowa Kirin Co., Ltd.· Source
Recruiting
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
NCT05967689· Phase 2· Taiho Oncology, Inc.· Source
Contact: Taiho Oncology, INC
Recruiting
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
NCT05392764· Phase 3· Juntendo University· Source
Contact: Koichiro Matsumura
Active, not recruiting
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
NCT04607421· Phase 3· Pfizer· Source
Active, not recruiting
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)
NCT04661007· Phase 1/2· Incyte Biosciences Japan GK· Source
Active, not recruiting
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance
NCT04285086· Phase 3· PharmaEssentia· Source
Active, not recruiting
A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer
NCT03807778· Phase 1· Takeda· Source
Active, not recruiting
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT03052608· Phase 3· Pfizer· Source
Active, not recruiting
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022· Phase 2· Astellas Pharma Global Development, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
NCT06412848· Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany· Source
Completed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890· Phase 2· Kyowa Kirin Co., Ltd.· Source
Terminated
Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated
NCT04778397· Phase 3· Gilead Sciences· Source
Completed
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
NCT03412773· Phase 3· BeiGene· Source
Completed
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
NCT03260894· Phase 3· Incyte Corporation· Source
Completed
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
NCT03358472· Phase 3· Incyte Corporation· Source
Completed
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)
NCT03268954· Phase 3· Takeda· Source
Completed
A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
NCT02684006· Phase 3· Pfizer· Source
Report an error